Alison co-heads our international Life Sciences and Healthcare group. She works with international life sciences companies to cut through the complexity of EU regulation of medical devices and pharmaceuticals, and get their products to market.

In a career of over 20 years, Alison has helped hundreds of life sciences companies manage the range of legal challenges involved in commercialising medical devices and medicinal products. She combines an encyclopaedic knowledge of the EU and UK life sciences regulatory environment with an analytical understanding of strategy and business in the life sciences sector. 

Alison provides sophisticated advice on regulation, compliance and commercialisation, as well as intellectual property transactions. On a number of occasions, she has successfully persuaded regulators and notified bodies to reconsider and ultimately overturn their decisions, allowing her clients to commercialise new products.

Alison supports clients on outright acquisitions and licences, as well as in due diligence for sizeable corporate transactions and listings. She also helps clients navigate the nuances of structuring and negotiating arrangements with various commercial and health care partners within the complex framework of EU regulations, national laws and industry and deontological codes. 

Her clients praise the pragmatism and commercial awareness she brings to every legal challenge and transaction, as well as her bright and personable working style. She is an accomplished leader, having built new life sciences practices for two top-tier London law firms.

Alison is a fluent French speaker.

Show full CV Hide full CV

Latest news & insights

Life sciences & healthcare

Renowned Life Sciences specialist Alison Dennis joins Taylor Wessing

1 May 2020

by multiple authors

Click here to find out more
Alison Dennis
Life sciences & healthcare

Taylor Wessing makes senior hire in Life Sciences and Healthcare Sector group

29 July 2019

by Shane Gleghorn and Alison Dennis

Click here to find out more
office-building-facades
Private equity

Advising The Rohatyn Group on investment in Optimapharm d.d.

22 May 2020
QUICK READ

by multiple authors

Click here to find out more
rolled up newspapers
Copyright & media law

COVID-19: Exceptional postponement of intellectual property deadlines in France

22 May 2020
QUICK READ

by multiple authors

Click here to find out more

Related people

Meet me at

There are no upcoming events